<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229799</url>
  </required_header>
  <id_info>
    <org_study_id>135.315</org_study_id>
    <nct_id>NCT02229799</nct_id>
  </id_info>
  <brief_title>Protocol for Post Marketing Surveillance of Actilyse Vial</brief_title>
  <official_title>Protocol for Post Marketing Surveillance of Actilyse Vial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objectives of this study are to review the safety and efficacy of Actilyse Vial&#xD;
      (hereafter referred to as &quot;Actilyse&quot;) in post-marketing use for treatment of acute ischemic&#xD;
      stroke, through investigating followings;&#xD;
&#xD;
        1. Unknown adverse events (especially serious adverse events)&#xD;
&#xD;
        2. Frequency (Incidence) and trend of adverse events under the actual practice&#xD;
&#xD;
        3. Factors on the safety profile of Actilyse&#xD;
&#xD;
        4. Factors on the efficacy profile of Actilyse&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2003</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical effectiveness assessed by 30 days-mortality</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant abnormal findings in physical examination</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">265</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Stroke patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actilyse</intervention_name>
    <arm_group_label>Stroke patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with acute ischemic stroke&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All in/out patients diagnosed as acute ischemic stroke&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Actilyse should not be administered to patients with high risk as follows:&#xD;
&#xD;
               -  Significant bleeding disorder at present or within the past 6 months, known&#xD;
                  hemorrhagic diathesis&#xD;
&#xD;
               -  Patients receiving oral anticoagulants, e.g. warfarin sodium (INR &gt; 1.3)&#xD;
&#xD;
               -  Manifest bleeding or recent severe or dangerous bleeding&#xD;
&#xD;
               -  History or evidence or suspicion of intracranial hemorrhage including&#xD;
                  sub-arachnoid hemorrhage&#xD;
&#xD;
               -  Any history of central nervous system damage (i.e. neoplasm, aneurysm,&#xD;
                  intracranial or spinal surgery)&#xD;
&#xD;
               -  Hemorrhagic retinopathy (e.g. in diabetes, vision disturbances may indicate&#xD;
                  hemorrhagic retinopathy) or other hemorrhagic ophthalmic conditions&#xD;
&#xD;
               -  Prolonged or traumatic cardiopulmonary resuscitation (&gt; 2 minutes), obstetrical&#xD;
                  delivery, within the past 10 days, recent puncture of a non-compressible&#xD;
                  blood-vessel (e.g. subclavian or jugular vein puncture)&#xD;
&#xD;
               -  Severe uncontrolled arterial hypertension&#xD;
&#xD;
               -  Bacterial endocarditis or pericarditis&#xD;
&#xD;
               -  Acute pancreatitis&#xD;
&#xD;
               -  Documented ulcerative gastrointestinal disease within the past 3 months,&#xD;
                  oesophageal varices, arterial-aneurysms, or arterial/venous malformations&#xD;
&#xD;
               -  Neoplasm with increased bleeding risk&#xD;
&#xD;
               -  Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal&#xD;
                  hypertension (oesophageal varices) and active hepatitis&#xD;
&#xD;
               -  Hypersensitive to the active substance alteplase or to any of the excipients&#xD;
&#xD;
          2. In cases of acute myocardial infarction and acute pulmonary embolism, any history of&#xD;
             stroke should be contraindicated.&#xD;
&#xD;
          3. In case that Actilyse is administered to acute ischaemic stroke, the followings should&#xD;
             be contraindicated:&#xD;
&#xD;
               -  Symptoms of ischemic attack began more than 3 hours prior to infusion start or&#xD;
                  when time of symptom onset is unknown,&#xD;
&#xD;
               -  Symptoms of acute ischemic stroke that were either rapidly improving or only&#xD;
                  minor before start of infusion&#xD;
&#xD;
               -  Severe stroke as assessed clinically and/or by appropriate imaging techniques,&#xD;
&#xD;
               -  Seizure at onset of stroke&#xD;
&#xD;
               -  Evidence of intracranial hemorrhage (ICH) on the CT-scan&#xD;
&#xD;
               -  Symptoms suggestive of subarachnoid hemorrhage, even if CT-scan is normal&#xD;
&#xD;
               -  Administration of heparin within 48 hours preceding the onset of stroke with an&#xD;
                  elevated activated partial thromboplastin time (aPTT) at presentation&#xD;
&#xD;
               -  A combination of previous stroke and diabetes mellitus&#xD;
&#xD;
               -  Prior stroke or head trauma within the past 3 months&#xD;
&#xD;
               -  Platelet count of less than 100,000/mm3&#xD;
&#xD;
               -  Systolic blood pressure&gt;185 mm Hg, or diastolic blood pressure&gt;110 mm Hg, or&#xD;
                  aggressive management (IV medication) is necessary to reduce blood pressure to&#xD;
                  these limits&#xD;
&#xD;
               -  Blood glucose&lt;50mg/dl or &gt;400 mg/dl&#xD;
&#xD;
          4. Acute stroke patients between the age of ≤ 18 or ≥ 80 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2014</study_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

